Biotech fundraising tracker reports $70M Series C for Ratio Therapeutics and $130M Series B for Crystalys Therapeutics

The Fierce Biotech Fundraising Tracker continues to log only large venture capital rounds, focusing on deals of $50 million or more.

Ratio Therapeutics secured a $70 million Series C, backed by investors including Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. The company plans to move its lead candidate, RTX-2358, into a combined phase 1/2 study for advanced sarcomas and to expand its oncology pipeline and manufacturing capacity.

Crystalys Therapeutics raised $130 million in a Series B round with participation from a broad group of investors such as Frazier Life Sciences, Wellington Management, Novo Holdings, SR One, and several other venture funds. The funding will support the company’s ongoing development programs, though specific uses were not detailed in the announcement.